Abstract
Factor concentrate products have changed significantly over the last decade. Efficacy of concentrates has been very good with adequate hemostasis being achieved utilizing most concentrates. However, two issues have emerged regarding concentrates, their safety, that is freedom from transfusion transmitted viruses, and their purity. Newer products are now available that are both much safer and highly pure.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
Literatur
Bell BA, Kurcynski EM, Bergman G. Inhibitors to monoclonal antibody verified factor VIII. Lancet 1990; 335:638
Kessler CM, Sachs K. Factor VIII: C inhibitor associated with monoclonal antibody purified Factor VIII concentrate Lancet 1990; 335:1403
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1993 Springer-Verlag Berlin Heidelberg
About this paper
Cite this paper
Brettler, D.B. (1993). Experience with New Clotting Products in the Treatment of Hemophilia-Related Bleeding Episodes. In: Scharrer, I., Schramm, W. (eds) 23. Hämophilie-Symposion. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-78359-3_53
Download citation
DOI: https://doi.org/10.1007/978-3-642-78359-3_53
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-540-56955-8
Online ISBN: 978-3-642-78359-3
eBook Packages: Springer Book Archive